公开(公告)号：US20180264015A1

公开(公告)日：2018-09-20

申请号：US15762644

申请日：2016-09-29

申请人： OSAKA UNIVERSITY

发明人： Nobuyuki TAKAKURA ,  Hisamichi NAITO ,  Kazuhiro TAKARA

IPC分类号： A61K31/662 ,  A61K45/00 ,  A61K35/17 ,  A61P37/04 ,  A61K38/00 ,  A61P35/00 ,  A61K39/395

CPC分类号： A61K31/662 ,  A61K31/683 ,  A61K31/685 ,  A61K35/17 ,  A61K38/005 ,  A61K39/39558 ,  A61K45/00 ,  A61K45/05 ,  A61P35/00 ,  A61P37/04

摘要： A lysophospholipid receptor-activating substance is able to normalize abnormal blood vessels in tumors without affecting normal blood vessels and to thus induce or promote infiltration of leukocytes into the whole or partial region of a tumor. Therefore, such a lysophospholipid receptor-activating substance is useful as a leukocyte infiltration promoter and an antitumor immunostimulant. Moreover, such a lysophospholipid receptor-activating substance can enhance cancer immunotherapy when used in combination with cancer immunotherapy, and is therefore useful as an agent for enhancing cancer immunotherapy.

公开(公告)号：US20230146210A1

公开(公告)日：2023-05-11

申请号：US17518212

申请日：2021-11-03

申请人： MITSUBISHI TANABE PHARMA CORPORATION ,  OSAKA UNIVERSITY

发明人： Maiko HAMADA ,  Yuki ARAI ,  Shuhei YAMAKOSHI ,  Hiroko WADA ,  Kazufumi OTSUKI ,  Hiroaki SHITAMA ,  Nobuyuki TAKAKURA

IPC分类号： C07F9/568 ,  C07F9/58 ,  A61K45/06

CPC分类号： C07F9/568 ,  C07F9/58 ,  A61K45/06

摘要： The present invention aims to provide a compound acting as a specific agonist for LPA4 receptors, and a pharmaceutical composition containing the compound. The present invention relates to a novel lysophosphatidic acid derivative having an agonistic action on LPA4 receptors and useful for the prophylaxis and/or treatment of diseases associated with angiogenesis abnormalities involving LPA4 receptors, diseases associated with vascular disorders, or the symptoms associated therewith, and a pharmaceutical composition containing the derivative.

公开(公告)号：US20220275343A1

公开(公告)日：2022-09-01

申请号：US17638026

申请日：2020-10-07

申请人： OSAKA UNIVERSITY

发明人： Nobuyuki TAKAKURA ,  Hisamichi NAITO ,  Taku WAKABAYASHI ,  Tomohiro IBA

IPC分类号： C12N5/071

摘要： The present invention provides a method for artificially producing a vascular endothelial stem cell from a non-vascular endothelial stem cell. The method for producing a vascular endothelial stem cell of the present invention comprises the step of bringing a vascular endothelial cell possessing no stem cell properties into contact with a factor secreted by an organ of a neonatal or juvenile mammal. The step may be a step of (1) transplanting the vascular endothelial cell possessing no stem cell properties into the organ of the neonatal or juvenile mammal, wherein the mammal is a non-human mammal, or (2) culturing the vascular endothelial cell possessing no stem cell properties in a culture system containing the factor secreted by the organ of the neonatal or juvenile mammal.

公开(公告)号：US20190328757A1

公开(公告)日：2019-10-31

申请号：US16310128

申请日：2017-06-15

申请人： OSAKA UNIVERSITY

发明人： Nobuyuki TAKAKURA ,  Daisuke EINO

IPC分类号： A61K31/685 ,  A61K39/395 ,  A61P43/00 ,  C07K16/28

摘要： Provided are agents comprising a phosphatidylcholine as an active ingredient to serve as a vein-formation promoting agent capable of promoting vein-like morphological change of tumor vessels, a vessel-diameter enlarging agent capable of enlarging the diameter of tumor vessels, a blood vessel-connection promoting agent capable of promoting connection of tumor vessels to each other without mediation of a lysophospholipid receptor, a leukocyte-infiltration promoting agent capable of promoting infiltration of leukocytes throughout a tumor region without mediation of a lysophospholipid receptor, and an antitumor immunostimulatory agent capable of promoting infiltration of leukocytes throughout a tumor region without mediation of a lysophospholipid receptor.